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Arsenic is one of the most common envi-
ronmental pollutants, occurring naturally in 
rocks, soil, and water. It can be released into 
the environment through natural activities or 
human actions. While human arsenic expo-
sure may occur through environmental, occu-
pational, and medicinal sources, contaminated 
drinking water is the main source of general 
population exposure. Arsenic levels in drink-
ing water often exceed many times the World 
Health Organization’s recommendation of 
10 ppb (10 μg/L), affecting tens of millions 
of people in the United States and many 
other countries (States et al. 2009; Tapio and 
Grosche 2006). Although epidemiological 
studies have consistently shown that long-
term arsenic exposure through drinking water 
is associated with increased risks of skin, lung, 
bladder, liver, and prostate cancers, the under-
lying mechanisms have not been elucidated 
(Benbrahim-Tallaa and Waalkes 2008; Celik 
et al. 2008; Liu and Waalkes 2008; Tapio and 
Grosche 2006).
Chronic exposure to arsenic causes malig-
nant transformation of various animal and 
human cells. For example Zhao et al. (1997) 
reported that sodium arsenite (0.5 μM) 
induced transformation of rat liver epithelial 
TRL 1215 cells, which was accompanied 
by a morphological change of the cells from 
epithelioid to fibroblast-like. Subcutaneous 
xenograft tumors produced by inoculation of 
arsenic-transformed TRL 1215 cells showed 
frequent invasion into the subdermal muscle 
layers and a high proportion of metastases to 
the lung (Zhao et al. 1997). Achanzar et al. 
(2002) found that chronic arsenite (5 μM) 
exposure caused transformation of immortal-
ized human prostate epithelial RWPE-1 cells. 
When inoculated into the renal capsules of 
male NCr-nu nude mice, arsenite-transformed 
RWPE-1 cells produced undifferentiated epi-
thelial tumors that frequently invaded into the 
surrounding capsular muscle tissue (Achanzar 
et al. 2002). Our recent study showed that 
arsenite (2.5 μM) exposure caused depletion of 
microRNA 200b (one of a large family of small 
non-coding RNAs; miR-200b), epithelial-to-
mesenchymal transition (EMT), and malig-
nant transformation of immortalized human 
bronchial epithelial cells (HBECs) (Wang et al. 
2011). Subcutaneous inoculation of arsenic-
transformed HBECs (As-transformed HBECs) 
produced undifferentiated lung epithelial cell-
derived xenograft tumors in Nu-Nu nude mice 
(Wang et al. 2011; Yang 2011). EMT enables 
cells to adopt a spindle-shaped   fibroblast-like 
morphology with enhanced migratory capac-
ity and invasiveness, and EMT is believed to 
play an important role in tumor progression 
by promoting tumor invasion and metastasis 
(Lee et al. 2006; Thiery et al. 2009). Therefore, 
findings from our study along with those 
of others (Zhao et al. 1997; Achanzar et al. 
2002) showing invasive xenograft tumor for-
mation in nude mice resulting from inocu-
lation of As-transformed cells suggest that 
As-transformed cells may have developed 
strong migratory and invasive capabilities. 
However, the migratory and invasive potential 
of As-transformed cells has rarely been studied.
The present study was designed to inves-
tigate the migratory and invasive behavior of 
As-transformed HBECs and the underlying 
mechanism. We found that As-transformed 
HBECs display highly migratory and inva-
sive potentials, and the nude mouse xenograft 
tumors resulting from subcutaneous inocula-
tion of As-transformed HBECs were capable of 
invading into surrounding fat tissues and form-
ing tubelike structures. Although both Akt (also 
known as protein kinase B) and extracellular 
signal–regulated protein kinase 1/2 (Erk1/2) 
were strongly activated in As-transformed 
HBECs, it is Akt, and not Erk1/2, activation 
that plays a key role in enabling cell migra-
tion and invasion. Moreover, we demonstrated 
that Akt activation drives As-transformed 
HBEC migration and invasion by promoting 
the expression of EMT-inducing transcription 
  factors zinc-finger E-box–binding homeobox 
factor 1 (ZEB1) and ZEB2.
Materials and Methods
Cell culture. Immortalized HBECs with intact 
p53 expression and function and HBECs 
with p53 expression stably knocked down 
(p53lowHBECs), which were generated from 
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Ba c k g r o u n d: Arsenic is one of the most common environmental contaminants. Long-term 
  exposure to arsenic causes human bronchial epithelial cell (HBEC) malignant transformation and 
lung cancer. However, the mechanism of arsenic lung carcinogenesis is not clear, and the migratory 
and invasive properties of arsenic-transformed cells (As-transformed cells) have rarely been studied.
oBjectives: This study was designed to investigate the migratory and invasive behavior of 
As-transformed HBECs and the underlying mechanism.
Me t h o d s : As-transformed p53lowHBECs were generated by exposing p53-knockdown HBECs 
to sodium arsenite (2.5 μM) for 16 weeks. Cell migration was assessed by transwell migration and 
wound-healing assay. Cell invasion was evaluated using Matrigel-coated transwell chambers. Gene 
overexpression, small interfering RNA (siRNA) knockdowns, and pharmacological inhibitors were 
used to determine the potential mechanism responsible for enhanced cell migration and invasion.
re s u l t s: Transwell migration and invasion assays revealed that As-transformed p53lowHBECs 
were highly migratory and invasive. Akt (also known as protein kinase B) and extracellular signal–
regulated protein kinase 1/2 (Erk1/2) were strongly activated in As-transformed p53lowHBECs. 
Stable expression of microRNA 200b in As-transformed p53lowHBECs abolished Akt and Erk1/2 
activation and completely suppressed cell migration and invasion. Pharmacological inactivation of 
Akt but not Erk1/2 significantly decreased cell migration and invasion. Inhibition of Akt reduced 
the expression of epithelial-to-mesenchymal transition–inducing transcription factors zinc-finger 
E-box–binding homeobox factor 1 (ZEB1) and ZEB2. siRNA knockdown of ZEB1 and ZEB2 
impaired As-transformed p53lowHBEC migration and invasion.
co n c l u s i o n s: Akt activation plays a critical role in enabling As-transformed HBEC migration and 
invasion by promoting ZEB1 and ZEB2 expression.
key w o r d s : Akt, arsenic, EMT, Erk1/2, human bronchial epithelial cells (HBECs), invasion, 
microRNA 200b (miR-200b), migration, PI3K. Environ Health Perspect 120:92–97 (2012).  http://
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the parental HBECs by expressing a short 
hairpin RNA targeting p53, were generously 
provided by J.D. Minna (University of Texas 
Southwestern Medical Center, Dallas, TX, 
USA) (Ramirez et al. 2004; Sato et al. 2006; 
Wang et al. 2011). Both p53-intact HBECs 
and p53lowHBECs were cultured in chemi-
cally defined serum-free medium (K-SFM; 
Invitrogen, Carlsbad, CA, USA) supplemented 
with 20 μg/mL of bovine pituitary extract and 
0.8 μg/mL epidermal growth factor (EGF). The 
cell transformation experiment was previously 
performed by continuous exposure of HBECs 
and p53lowHBECs to arsenic (sodium arsen-
ite, 2.5 μM) for 16 weeks (Wang et al. 2011). 
Sixteen-week arsenic exposure caused malignant 
transformation of only p53lowHBECs and not 
p53-intact HBECs (Wang et al. 2011). Arsenic-
transformed cells (As-transformed p53lowH-
BECs) were cultured in K-SFM as above with 
the same supplements in the absence of arsenic.
Transwell cell migration and invasion 
assay. Control cell and As-transformed cell 
migration and invasion were quantified by 
transwell assays using uncoated (8 μm pore 
size; Corning Costar, Cambridge, MA, USA) 
or growth factor–reduced Matrigel™-coated fil-
ters (8 μm pore size; BD Biosciences, Franklin 
Lakes, NJ, USA) in 24-well plates, respec-
tively. Briefly, cells were trypsinized and seeded 
onto the upper chamber of the transwells 
(5 × 104 cells/well) in supplement-free K-SFM. 
The lower chamber of the transwells was filled 
with K-SFM containing 100 ng/mL EGF. The 
chambers were incubated at 37°C with 5% 
CO2 for 6 hr (migration assay) or 24 hr (inva-
sion assay). At the end of incubation, cells on 
the upper surface of the filter were removed 
using a cotton swab. Cells migrating or invad-
ing through the filter to the lower surface were 
fixed with 4% paraformaldehyde for 10 min 
and stained with 0.1% crystal violet for 5 min. 
Migrated or invaded cells were viewed and 
photographed under a phase-contrast micro-
scope and counted in five fields (100× magnifi-
cation). The fields were randomly chosen from 
the top, bottom, left, right, and center position 
of each filter. The person who counted the cells 
was not aware of which experimental group of 
cells was being counted. The experiments were 
performed in triplicate wells and performed 
two to three times.
Wound-healing cell migration assay. To 
examine the effect of inhibition of phospho-
inositide 3-kinase (PI3K), Akt, or Erk1/2 
on cell migration, a wound-healing assay 
was performed. Briefly, As-transformed cells 
were seeded into 6-cm dishes and allowed 
to form confluent monolayers. Cell mono-
layers were scratched using a 200-μL pipette 
tip to create a wound and washed once with 
  phosphate-buffered saline (PBS); then we 
added fresh K-SFM culture medium supple-
mented with 1 μg/mL of the proliferation 
inhibitor mitomycin C (Sigma, St. Louis, 
MO, USA), and vehicle control [dimethyl 
sulfoxide (DMSO); Sigma], 1 μM of the 
PI3K inhibitor wortmannin (EMD Chemicals 
USA, Gibbstown, NY, USA), 5 μM of the 
Akt inhibitor VIII trifluoroacetate salt hydrate 
(Sigma), or 2.5 μM of the MEK1 [mitogen- 
activated protein kinase (MAPK)/ERK 
kinase 1] inhibitor U0126 (EMD Chemicals 
USA). Wound width was monitored over time 
by microscopy and photographed immedi-
ately after inhibitors were added in (0 hr) and 
after a 20-hr incubation. Wortmannin (1 μM) 
was added in again after 10 hr of incubation. 
The experiments were performed in triplicate 
dishes and repeated two to three times.
Generation of cells stably expressing miR-
200b. Establishment of stable expression of 
miR-200b in As-transformed p53lowHBEC 
cells was described in detail previously (Wang 
et al. 2011).
Western blot analysis. Cells were lysed using 
Tris-sodium dodecyl sulfate (SDS) as described 
by Yang et al. (2006) and subjected to SDS–
polyacrylamide gel electrophoresis (10–50 μg 
of protein/lane). The following primary anti-
bodies were used: anti-phosphorylated-Akt 
(Ser473), anti-phosphorylated-Akt (Thr308), 
anti-total-Akt, anti-phosphorylated-Erk1/2, 
anti-total-Erk1/2, anti-phosphorylated-p38, 
anti-phosphorylated-JNK (c-jun N-terminal 
kinase)  (Cell  Signaling  Technology, 
Beverly, MA, USA); anti-ZEB1 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA); 
anti-ZEB2 (Novus Biologicals, Littleton, CO, 
USA); and anti-β-actin (Sigma).
ZEB1 and ZEB2 RNA interference. 
Negative control small interfering RNA 
(siRNA) and ON-TARGETplus SMARTpool 
siRNA for ZEB1 and ZEB2 were obtained 
from Thermo Scientific Dharmacon (Lafayette, 
CO, USA). To investigate the role of ZEB1 
and ZEB2 in As-transformed cell migration 
and invasion, siRNA duplexes (100 nM) were 
transfected into cells using Lipofectamine 
2000 (Invitrogen) in serum-free medium as 
described previously (Wang et al. 2011). For 
simultaneous knockdown of both ZEB1 and 
ZEB2, 50 nM of ZEB1 and 50 nM of ZEB2 
siRNA duplexes were used. Forty-eight hours 
after transfection, cells were collected for tran-
swell migration/invasion assay and Western 
blot analysis as described above.
Thyroid transcription factor 1 immuno-
fluorescence staining. Nude mouse subcuta-
neous xenograft tumor tissue sections (5 μm) 
from our previous study were prepared and 
subjected to hematoxylin and eosin and 
immuno  fluorescence staining as described pre-
viously (Wang et al. 2011; Yang 2011). Anti-
thyroid transcription factor 1 (anti-TTF-1; 
sc-13040) primary antibody was obtained from 
Santa Cruz Biotechnology. Slides were counter-
stained with 4´,6-di  amidino-2-phenyl  indole 
(DAPI). The stained sections were visualized 
with a Nikon Eclipse TE2000-U fluorescence 
microscope (Nikon, Inc., Melville, NY, USA). 
The captured red fluorescent images (TTF-
1–positive staining) were overlaid with the blue 
fluorescent images (nucleus DAPI staining) 
using MetaMorph software (Molecular Devices 
Corp., Downington, PA, USA).
Statistical analysis. The statistical analyses 
for the significance of differences in numeri-
cal data (means ± SDs) were performed using 
two-tailed t-tests for comparison of two data 
sets or one-way analysis of variance for mul-
tiple data sets. A p-value of < 0.05 was consid-
ered statistically significant.
Results
As-transformed p53lowHBECs exhibit high 
migratory and invasive potentials. We recently 
found that subcutaneous inoculation of 
As-transformed p53lowHBECs into nude mice 
produced undifferentiated lung epithelial-
  derived xenograft tumors (Wang et al. 2011; 
Yang 2011). Histological analysis revealed 
that the mouse xenograft tumors were capable 
of invading into surrounding fat tissues and 
forming tubelike structures [see Supplemental 
Material, Figure 1 (http://dx.doi.org/10.1289/
ehp.1104061)]. Extensive positive staining 
of TTF-1, which is present in the epithelium 
of the lung and used as a marker of human 
primary lung tumors (Reis-Filho et al. 2000), 
was detected in xenogaft tumors (Yang 2011) 
and their surrounding tubelike structures 
(Supplemental Material, Figure 2). These 
results suggest that mouse xenograft tumors 
resulting from subcutaneous inoculation 
of As-transformed HBECs display a strong 
invasive property. This finding is consistent 
with previous studies showing that inocula-
tion of rat liver epithelial As-transformed cells 
or human prostate epithelial cells grew inva-
sive tumors in immunocompromised mice 
(Achanzar et al. 2002; Zhao et al. 1997). 
However, the migratory and invasive behavior 
of As-transformed cells has been rarely studied. 
Because EMT enables cell to move and invade 
(Lee et al. 2006; Thiery et al. 2009), we exam-
ined the migratory and invasive properties of 
As-transformed HBECs that underwent EMT. 
Control HBECs and p53lowHBECs displayed 
weak migratory and invasive capability as 
determined by transwell migration and inva-
sion assays (Figure 1A,B,D,E). In striking con-
trast, As-transformed p53lowHBECs showed 
strong migratory capacity (Figure 1B,C) and 
invasive potential (Figure 1E,F). Consistent 
with our previous finding that HBECs 
exposed to arsenic for 16 weeks did not 
undergo EMT and malignant transforma-
tion (Wang et al. 2011), As-exposed HBECs 
exhibited only weak migration and invasion 
comparable to that of control HBECs. These 
results along with our recent findings indicate Wang et al.
94  v o l u m e  120 | n u m b e r 1 | January 2012  •  Environmental Health Perspectives
that As-transformed p53lowHBECs are highly 
migratory and   invasive.
Stable reexpresson of miR-200b com-
pletely inhibits As-transformed HBEC migra-
tion and invasion. Stable reexpresson of 
miR-200b in As-transformed p53lowHBECs 
reversed their transformed phenotypes, as evi-
denced by inhibition of colony formation in 
soft agar and prevention of xenograft tumor 
formation in nude mice (Wang et al. 2011). 
We then wanted to determine whether sta-
bly reexpressing miR-200b has an effect on 
As-transformed p53lowHBEC migratory and 
invasive behavior. Green fluorescent protein 
(GFP) vector control cells displayed similar 
migratory (Figure 2A,C) and invasive poten-
tials (Figure 2B,D), comparable to those of 
As-transformed p53lowHBECs. However, cells 
stably expressing miR-200b lost the migratory 
and invasive capability, exhibiting only weak 
migration and invasion similar to that of non-
transformed cells (compare Figures 1 and 2). 
These results indicate that stably reexpressing 
miR-200b completely inhibits As-transformed 
HBEC migration and invasion.
MiR-200b abolishes Akt and Erk1/2 acti-
vation in As-transformed HBECs. Previous 
studies have shown that arsenic exposure can 
activate Akt, Erk1/2, p38, and JNK path-
ways and that Akt and Erk1/2 activation plays 
important roles in arsenic-induced cell trans-
formation (Eblin et al. 2007; Huang et al. 
1999). However, it remains to be determined 
whether Akt, Erk1/2, or another signaling 
pathway activation is responsible for promot-
ing As-transformed cell migration and inva-
sion. We first examined the activation status 
of Akt, Erk1/2, p38, and JNK in control cells, 
As-exposed HBECs, and As-transformed 
p53lowHBECs. Strikingly, Akt, Erk1/2, and 
p38 MAPK were highly phosphorylated in 
As-transformed p53lowHBECs (Figure 3A), 
whereas no dramatic differences of JNK phos-
phorylation were detected between control 
cells and As-exposed HBECs. Since stably 
reexpressing miR-200b completely inhibited 
As-transformed p53lowHBEC migration and 
invasion, we next determined the effect of 
miR-200b on Akt, Erk1/2, and p38 activa-
tion status in As-transformed p53lowHBECs. 
Stable reexpression of miR-200b abolished 
Akt and Erk1/2 phosphorylation but had no 
effect on p38 phosphorylation (Figure 3B). 
These results suggest that activation of Akt 
and Erk1/2, but not p38, may contribute to 
enhanced migratory and invasive behavior of 
As-transformed p53lowHBECs.
Akt but not Erk1/2 activation enables 
As-transformed HBEC migration and inva-
sion. To determine the potential role of Akt 
and/or Erk1/2 activation in cell migration 
and invasion, As-transformed p53lowHBECs 
were treated with a PI3K inhibitor (wortman-
nin), an Akt inhibitor, or an MEK1 inhibitor 
Figure 1. As-transformed p53lowHBECs are highly migratory and invasive. (A, B, D, and E) Representative 
images of transwell cell migration (A and B) and invasion (D and E) assays. For details, see “Materials and 
Methods.” Bars = 100 μm. (C and F) Quantification of transwell cell migration (C) and invasion (F) assays 
(means ± SDs, n = 3). Similar results were obtained in two additional experiments. 
*p < 0.05, compared to vehicle control–exposed cells or As-transformed HBECs. 
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Figure 2. Stable reexpression of miR-200b completely inhibits As-transformed HBEC migration and invasion. 
(A and B) Representative images of transwell cell migration (A) and invasion (B) assays, as described in 
“Materials and Methods.” Bars = 100 μm. (C and D) Quantification of transwell cell migration (C) and inva-
sion (D) assays (means ± SD, n = 3). Similar results were obtained in two additional experiments.
*p < 0.05, compared with As-transformed p53lowHBEC-GFP cells. 
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(U0126) that blocks Erk1/2 activation. As 
expected, wortmannin and the Akt inhibi-
tor efficiently and dose-dependently inhibited 
Akt phosphoryla  tion with no significant effect 
on Erk1/2 phosphorylation, whereas U0126 
efficiently suppressed Erk1/2 phosphoryla-
tion with no effect on Akt phosphorylation 
(Figure 4A). The wound-healing assay revealed 
that wortmannin and Akt inhibitor treat-
ment significantly reduced wound closure, 
indicating significant inhibition of cell migra-
tion (Figure 4B). In contrast, inhibition of 
Erk1/2 by U0126 showed no significant effect 
on wound closure, indicating no inhibition 
of cell migration. These effects were further 
confirmed by using transwell cell migration 
and invasion assays (Figure 4C). Treatment 
with wortmannin and Akt inhibitor signifi-
cantly reduced cell migration and invasion by 
80–85% and 75–77%, respectively. However, 
treatment with U0126 only slightly reduced 
cell migration and invasion, by 12% and 10%, 
respectively (Figure 4C). These results indicate 
that it is mainly the Akt activation that drives 
As-transformed HBEC migration and invasion.
Akt activation enables As-transformed 
HBEC migration and invasion via promoting 
ZEB1 and ZEB2 expression. We investigated 
how Akt activation promotes As-transformed 
p53lowHBEC migration and invasion. We pre-
viously showed that arsenic exposure caused 
EMT through inducing the expression of 
ZEB1 and ZEB2 (Wang et al. 2011). ZEB1 
and ZEB2 are EMT-inducing transcription 
factors capable of promoting cell migration 
and invasion (Kim et al. 2011). We then 
examined whether inhibition of Akt activation 
Figure 3. Akt, Erk1/2, and p38 MAPK are highly activated in As-transformed HBECs, and stably reexpress-
ing miR-200b abolishes Akt and Erk1/2 activation. (A) Akt, Erk1/2, and p38 MAPK are highly activated only 
in As-transformed p53lowHBECs. (B) Stable reexpression of miR-200b abolishes Akt and Erk1/2 activation 
but has no effect on p38 MAPK activation in As-transformed p53lowHBECs. Similar results were obtained in 
two additional experiments.
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Figure 4. Inhibition of Akt but not Erk1/2 suppresses As-transformed HBEC migration and invasion. (A) Inhibition of Akt and Erk1/2 determined by Western blot 
analysis. (B) Inhibition of Akt but not Erk1/2 impairs As-transformed p53lowHBEC migration determined by the wound-healing assay. Bars = 100 μm. (C) Inhibition 
of Akt but not Erk1/2 suppresses As-transformed p53lowHBEC migration and invasion as determined by transwell migration/invasion assays (means ± SDs, n = 3). 
Similar results were obtained in two additional experiments. 
*p < 0.05, compared with vehicle control–treated cells. 
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has an effect on ZEB1 and ZEB2 expression. 
Figure 5A shows that treatment with wort-
mannin (1 μM) and an Akt inhibitor (5 μM), 
which efficiently reduced Akt phosphoryla-
tion and cell migration/invasion and greatly 
decreased the protein levels of ZEB1 and 
ZEB2. As expected with the lack of signifi-
cant effect on cell migration and invasion by 
inhibition of Erk1/2, treatment with U0126 
(2.5 μM) also did not reduce the protein levels 
of ZEB1 and ZEB2.
To determine the role of ZEB1 and ZEB2 
in As-transformed p53lowHBEC migration 
and invasion, the siRNA approach was used 
to knock down the expression of ZEB1 and 
ZEB2. Figure 5B shows efficient knockdown 
of ZEB1 and ZEB2 using ON-TARGETplus 
SMARTpool siRNA for ZEB1 and ZEB2 
(Wang et al. 2011) as determined by Western 
blot. Knockdown of either ZEB1 or ZEB2 
did not have a significant effect on cell migra-
tion and invasion (Figure 5C). However, 
simultaneous knockdown of both ZEB1 and 
ZEB2 significantly reduced cell migration and 
invasion, suggesting that there is an overlap 
function between ZEB1 and ZEB2 in pro-
moting cell migration and invasion. Together, 
these results indicate that Akt activation drives 
As-transformed HBEC migration and inva-
sion mainly through promoting ZEB1 and 
ZEB2 expression.
Discussion
Arsenic exposure represents a major environ-
mental health concernin causing cancers 
and other diseases. The mechanism of arse-
nic carcinogenesis, particularly of arsenic lung 
carcinogenesis, has not been elucidated. It is 
generally accepted that non  genotoxic modifica-
tions that lead to aberrant gene expression may 
play key roles in arsenic carcinogenesis (Arita 
and Costa 2009; Hernandez et al. 2009; Ren 
et al. 2011; Yang and Frenkel 2002). Indeed, 
studies have shown that abnormal cell signal-
ing and gene expression are critically involved 
in various animal and human cell transforma-
tion process by arsenic exposure (Eblin et al. 
2007; Huang et al. 1999; Ouyang et al. 2008; 
Wang et al. 2011). In the present study, we 
provided additional novel evidence suggesting 
that abnormal cell signaling and gene expres-
sion may play a crucial role in arsenic lung 
carcinogenesis by promoting As-transformed 
HBEC migration and invasion.
Arsenic-induced cell transformation has 
been reported to be accompanied by cellu-
lar morphological changes from epithelioid 
to fibroblast-like (Chang et al. 2010; Zhao 
et al. 1997). When inoculated into nude mice, 
rat liver epithelial As-transformed cells and 
human prostate epithelial cells produced inva-
sive xenograft tumors (Achanzar et al. 2002; 
Zhao et al. 1997). In addition, Wnek et al. 
(2010) found that the changes of expression 
of two biomarkers (cyclooxygenase-2 and gene 
promoter “deleted in bladder cancer 1”) of 
invasive bladder cancers were associated with 
monomethyl  arsonous acid–induced malig-
nant transformation of human urothelial 
cells (UROtsa). We found that subcutaneous 
inoculation of As-transformed HBECs into 
nude mice produced undifferentiated lung 
epithelial-derived xenograft tumors (Wang 
et al. 2011; Yang 2011), which were capable 
of invading into the surrounding fat tissues 
and forming tubelike structures. Furthermore, 
our and other recent studies (Li et al. 2011; 
Wang et al. 2011) demonstrated that arsenic 
exposure induced EMT of rat lung epithelial 
cells and HBECs, as evidenced by the appear-
ance of spindle-shaped morphology, loss of 
epithelial cell marker E-cadherin, and acquisi-
tion of mesenchymal cell markers vimentin 
and N-cadherin. EMT occurs as part of nor-
mal embryonic development, enabling cells 
to migrate; EMT is now viewed as an impor-
tant step in tumor invasion and metastasis 
(Kalluri and Weinberg 2009). Together, these 
findings indicate that investigating the migra-
tory and invasive properties of As-transformed 
cells is essential. The results presented here 
demonstrate that As-transformed HBECs 
obtained strong motile capacity and invasive 
potential. However, it is interesting to note 
that short-term (36 hr) sodium arsenite treat-
ment blocked chicken cardiac endothelial-to-
  mesenchymal transition (Lencinas et al. 2010), 
suggesting that arsenic may have differential 
effects on epithelial- versus endothelial-to-
mesenchymal transition.
Previous studies have shown that acute 
and chronic arsenic exposure activated Akt 
and Erk1/2 (Eblin et al. 2007; Simeonova 
et al. 2002). Akt and Erk1/2 activity were 
critically involved in arsenic-induced human 
and mouse cell transformation (Eblin et al. 
2007; Huang et al. 1999). Ouyang et al. 
(2008) further determined that Akt activation 
promoted human keratinocyte transformation 
by arsenic by increasing cyclin D1 expres-
sion. Collectively, these earlier studies showed 
critical roles for Akt and Erk1/2 activation in 
cell transformation by arsenic. Nevertheless, 
whether Akt or Erk1/2 activation or other 
abnormally activated signaling pathways play 
a role in migratory and invasive behavior of 
As-transformed cells had not been investi-
gated. By overexpressing miR-200b, apply-
ing pharmacological inhibitors to inactivate 
Akt or Erk1/2, and siRNA knockdown of 
the expression of ZEB1 and ZEB2, we estab-
lished that it is the activation of Akt, and not 
Erk1/2, that enables As-transformed HBECs 
to migrate and invade. These findings along 
with others mentioned above suggest that Akt 
activation not only plays important roles in 
the early-stages of arsenic carcinogenesis by 
promoting cell transformation, but also may 
play a key role in the late stages of arsenic 
carcinogenesis by driving As-transformed cell 
migration and invasion. This is consistent 
with previous studies showing hyperactivation 
of Akt in the majority of human lung cancers 
and inhibition of Akt suppressing metastatic 
potential of human lung cancer cells (Akca 
Figure 5. Inhibition of Akt decreases the expression of ZEB1 and ZEB2, and siRNA knockdown of ZEB1 and ZEB2 reduces As-transformed p53lowHBEC migra-
tion and invasion. (A) Inhibition of Akt but not Erk1/2 decreases the expression of ZEB1 and ZEB2. Wort., wortmannin. (B) siRNA knockdown of the expression of 
ZEB1 and ZEB2. (C) siRNA knockdown of ZEB1 and ZEB2 reduces As-transformed p53lowHBEC migration and invasion (means ± SDs, n = 3). Similar results were 
obtained in two additional experiments. 
*p < 0.05, compared with control siRNA-transfected cells. 
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et al. 2011; Altomare and Testa 2005; Ogata 
et al. 2011).
Arsenic exposure can activate Akt in a 
PI3K-depedent manner in human urothe-
lial cells and keratinocytes (Eblin et al. 2007; 
Ouyang et al. 2008). In addition, Zhang et al. 
(2011) recently found that down-regulation 
of protein phosphatase 2A and pleckstrin 
homology domain leucine-rich repeat protein 
phosphatase 2 contribute to Akt activation in 
arsenite-treated mouse epidermal JB6 Cl41 
cells. These findings indicate that different 
mechanisms of Akt activation by arsenic expo-
sure exist in different kinds of cells. In the 
present study, we found that Akt activation in 
As-transformed HBECs depended on PI3K 
activity as inhibition of PI3K diminished 
Akt phosphorylation at both serine 473 and 
threonine 308 sites. Moreover, inactivation 
of Akt by treatment with a PI3K inhibitor or 
an Akt inhibitor similarly and significantly 
reduced the expression of ZEB1 and ZEB2, 
cell migration, and invasion.
ZEB1 and ZEB2 are EMT-inducing tran-
scription factors (Peinado et al. 2007). Our 
recent study indicated that arsenic exposure 
caused EMT of p53lowHBECs by inducing the 
expression of ZEB1 and ZEB2 without affect-
ing the expression of other EMT-inducing 
transcription factors (Wang et al. 2011). While 
EMT is generally considered a late event in 
cancer progression, our and other recent find-
ings provide evidence that EMT may also play 
a role in arsenic-caused or tobacco-carcinogen–
caused HBEC transformation, the initial step 
of carcinogenesis (Tellez et al. 2011; Wang 
et al. 2011). Although we demonstrated an 
important role for Akt activation in promoting 
As-transformed HBEC migration and inva-
sion, it remains to be determined whether Akt 
is activated during the early stage of HBEC 
transformation and whether Akt activation is 
required for HBEC transformation by arse-
nic. Because Akt can be activated in human 
urothelial cells and keratinocytes during short- 
and long-term arsenic exposure (Eblin et al. 
2007; Ouyang et al. 2008), further studies are 
warranted to investigate Akt activation status 
in HBECs during early arsenic exposure and 
whether Akt activation contributes to HBEC 
transformation by arsenic. Findings from this 
and future studies will help establish Akt as a 
key molecular target for the prevention and 
treatment of human lung cancer resulting from 
arsenic exposure.
Conclusions
The present study is the first to focus on charac-
terizing As-transformed cell migratory and inva-
sive behavior and the underlying mechanism. 
We demonstrated that As-transformed HBECs 
have strong migratory and invasive capability. 
While both Akt and Erk1/2 are highly acti-
vated in As-transformed HBECs, it is mainly 
the activation of Akt, and not Erk/1/2, that 
enables As-transformed HBEC migration and 
invasion. Further, Akt activation drives cell 
migration and invasion through promoting 
the expression of EMT-inducing transcription 
factors ZEB1 and ZEB2. Given the critical 
role of Akt, ZEB1, and ZEB2 in cancer pro-
gression (Altomare and Testa 2005; LoPiccolo 
et al. 2008; Peinado et al. 2007), the findings 
from this study provide additional novel evi-
dence that Akt activation may play an impor-
tant role in arsenic lung carcinogenesis by 
promoting As-transformed HBEC   migration 
and   invasion.
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